Published in Ann Surg on August 01, 1990
Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg (1994) 1.41
Dormancy of metastatic melanoma. Pigment Cell Melanoma Res (2009) 1.19
Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg (2013) 1.18
Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg (1991) 1.07
Decoding melanoma metastasis. Cancers (Basel) (2010) 1.02
A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol (2013) 0.97
Malignant melanoma of the skin: long-term follow-up and time to first recurrence. World J Surg (2011) 0.91
Cancer Metastases: Early Dissemination and Late Recurrences. Cancer Growth Metastasis (2015) 0.86
Delayed systemic recurrence of uveal melanoma. Am J Clin Oncol (2013) 0.85
A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol (2012) 0.84
Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. PLoS One (2013) 0.83
Late recurrence of malignant melanoma presenting as small bowel intussusception. Dig Dis Sci (2006) 0.81
Mechanisms of Cancer Cell Dormancy-Another Hallmark of Cancer? Cancer Res (2015) 0.81
Complete resection of isolated pancreatic metastatic melanoma: a case report and review of the literature. World J Gastroenterol (2010) 0.80
Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review. Biomed Res Int (2015) 0.79
Late recurrence of malignant melanoma presenting with hemoptysis. Lung India (2010) 0.79
Long-term follow-up for melanoma patients: is there any evidence of a benefit? Surg Oncol Clin N Am (2015) 0.78
Bilateral choroidal metastases as presentation of dissemination of cutaneous malignant melanoma. Case Rep Ophthalmol Med (2012) 0.77
Risk factors for residual and recurrent and metastatic uveal melanoma after trans-scleral local resection. Br J Ophthalmol (1996) 0.75
An incidental finding of a nodal recurrence of cutaneous malignant melanoma after a 45-year disease-free period. BMJ Case Rep (2014) 0.75
Late recurrence of malignant melanoma. Ann Surg (1991) 0.75
Aggressive behaviour of metastatic melanoma in a patient with neurofibromatosis type 1. Case Rep Surg (2015) 0.75
Complete resection of isolated hepatic metastatic uveal melanoma with a notably long disease-free period: A case report and review of the literature. Oncol Lett (2015) 0.75
[Symptomatic impairment of urine transport after malignant melanoma of the choroid]. Ophthalmologe (2005) 0.75
Survival in metastatic ocular melanoma. Cancer (1983) 1.37
The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast Surg (1989) 1.21
Late recurrence of cutaneous melanoma. Arch Surg (1983) 1.16
Late relapse from cutaneous stage I malignant melanoma. Arch Surg (1985) 1.16
Late metastases (beyond ten years) of cutaneous malignant melanoma. Literature review and case report. J Am Acad Dermatol (1986) 1.08
Late recurrence (beyond ten years) of cutaneous malignant melanoma. Report of two cases and a review of the literature. JAMA (1984) 1.08
Recurrent malignant melanoma following a 46-year disease-free interval. N Y State J Med (1985) 0.99
Predictors of late deaths among patients with clinical stage I melanoma who have not had bony or visceral metastases within the first 5 years after diagnosis. J Am Acad Dermatol (1983) 0.96
Late recurrence of malignant melanoma. Am Fam Physician (1988) 0.95
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg (1998) 3.11
The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol (1989) 2.32
Metastatic melanoma in the thorax: report of 130 patients. AJR Am J Roentgenol (1981) 1.95
Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg (1995) 1.90
Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients. Surgery (1990) 1.72
MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J Immunol (1991) 1.60
Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. Surgery (1984) 1.59
Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg (1994) 1.56
Melanoma of the gallbladder: a review of cases seen at Duke University Medical Center. Cancer (1999) 1.54
Malignant melanoma and pregnancy. Cancer (1985) 1.47
Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg (1994) 1.41
Monoamine oxidase and catechol-O-methyltransferase activity in hamster and rat insulinomas. Diabetologia (1979) 1.41
Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. J Natl Cancer Inst (1993) 1.40
Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res (1994) 1.38
Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. Proc Natl Acad Sci U S A (1984) 1.33
Lethal "thin" malignant melanoma. Identifying patients at risk. Ann Surg (1988) 1.30
Skin graft rejection between subjects genotyped for HL-A. Transplant Proc (1969) 1.29
Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg (1992) 1.28
Mucosal melanoma of the female genitalia: a clinicopathologic study of forty-three cases at Duke University Medical Center. Surgery (1998) 1.28
Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg (1983) 1.26
Positron emission tomography scanning in malignant melanoma. Cancer (2000) 1.25
Central nervous system metastases in malignant melanoma. Neurosurgery (1981) 1.21
Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal. J Natl Cancer Inst (1977) 1.18
Selection of patients for heterotopic implantation of the areola and nipple. Surg Gynecol Obstet (1980) 1.17
Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery (1993) 1.16
Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. Ann Surg (2001) 1.15
Anomalous MLR responsiveness among siblings. Transplant Proc (1971) 1.15
Hepatobiliary cystadenoma with mesenchymal stroma. Ann Surg (1990) 1.14
Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg (1992) 1.13
Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy. Ann Surg (1989) 1.10
Incidence of anatomical variants in renal vasculature in the presence of normal renal function. Ann Surg (1978) 1.09
The role of resection in the management of melanoma metastatic to the adrenal gland. Surgery (1991) 1.09
Role of surgical intervention in the management of intestinal metastases from malignant melanoma. Am J Surg (1991) 1.08
Non-specific and specific immunotherapy in patients with melanoma. Surgery (1972) 1.06
Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet (1983) 1.06
Renal transplantation between HL-A identical donor-recipient pairs. Functional and morphological evaluation. J Clin Invest (1972) 1.05
Immunogenetics of consanguineous allografts in man. II. Correlation of renal allografting with HL-A genotyping. Ann Surg (1970) 1.04
Primary malignant melanoma of the esophagus. J Surg Oncol (1997) 1.04
Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg (2000) 1.03
Malignant melanoma arising during pregnancy. A study of 100 patients. Ann Surg (1990) 1.03
Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer (2000) 1.02
Specific active immunotherapy for melanoma. Ann Surg (1979) 1.02
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer (1980) 1.02
Malignant melanoma of the mucous membranes: a review of 119 cases. Ann Surg Oncol (1998) 1.01
Immunogenetics of consanguineous allografts in man. I. Histocompatibility testing and skin allografts. Ann Surg (1970) 1.01
The annual risk of melanoma progression. Implications for the concept of cure. Cancer (1992) 1.00
Malignant melanoma in black American and white American populations. A comparative review. JAMA (1982) 0.99
Subungual melanoma. A review of 93 cases with identification of prognostic variables. Clin Orthop Relat Res (2000) 0.98
Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. Cancer (1988) 0.98
Acral melanoma: a review of 185 patients with identification of prognostic variables. J Surg Oncol (1990) 0.98
Rejection of canine cardiac allografts. Am J Pathol (1968) 0.97
Postoperative function of "free" jejunal transplants for replacement of the cervical esophagus. Ann Surg (1980) 0.97
HL-A antigenic loss in malignant transformation. J Natl Cancer Inst (1971) 0.97
Current management of melanoma. Ann Surg (1977) 0.97
Prognosis for recurrent stage I malignant melanoma. Arch Surg (1987) 0.96
Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases. J Natl Cancer Inst (1988) 0.95
The immunogenicity of human HL-A haplotypesas measured by skin graft survival times and mixed leukocyte reactions. J Exp Med (1971) 0.95
Radiologic, endoscopic and surgical considerations of malignant melanoma metastatic to the small intestine. Curr Surg (1984) 0.94
Long-term clinical outcome of immediate reconstruction after mastectomy. Plast Reconstr Surg (1985) 0.93
Cloacogenic carcinoma. Ann Surg (1978) 0.93
Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg (1992) 0.93
Pectoralis pyomyositis: an unusual cause of chest wall pain in a patient with diabetes mellitus and rheumatoid arthritis. J Rheumatol (1986) 0.92
Sex related survival differences in instances of melanoma. Surg Gynecol Obstet (1984) 0.92
Melanoma of the foot. J Bone Joint Surg Am (1994) 0.91
HL A typing, mixed leukocyte reactivity, and skin graft survival in a family with a recombinant at the HL-1 chromosomal region (major transplantation region). Transplantation (1973) 0.91
Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg (1993) 0.91
Percutaneous transluminal renal artery angioplasty in a 3 1/2-year-old hypertensive girl. J Pediatr (1980) 0.90
Anorectal melanoma: clinical characteristics and the role of abdominoperineal resection. Ann Plast Surg (1992) 0.90
Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol (2001) 0.90
A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer (1997) 0.90
Ileocolonic perforation. A complication following renal transplantation. Am J Roentgenol Radium Ther Nucl Med (1975) 0.90
Computed tomography in the detection of abdominal metastases from malignant melanoma. Invest Radiol (1984) 0.89
The spectrum of small bowel melanoma. Gastrointest Radiol (1978) 0.89
Rationale for immediate reconstruction of the breast following modified radical mastectomy. Ann Plast Surg (1982) 0.89
Lymphoscintigraphy for malignant melanoma. Surgical considerations. Am Surg (1983) 0.89
Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. Cancer Res (1990) 0.88
Graft donor selection based upon single locus (haplotype) analysis within families. Transplantation (1968) 0.88
Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells. Cell Immunol (1996) 0.88
DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease. Pancreas (1988) 0.87
The incidence and management of pulmonary mycosis in renal allograft patients. Ann Surg (1975) 0.87
Stage II malignant melanoma: presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients. J Surg Oncol (1988) 0.87
Long-term results with forty-five living related renal allograft recipients genotypically identical for HLA. Surgery (1977) 0.87
Skeletal metastases of melanoma. J Bone Joint Surg Am (1978) 0.87
Metastatic melanoma to the spine. Demographics, risk factors, and prognosis in 114 patients. Spine (Phila Pa 1976) (1995) 0.86
Biliary cystadenoma with mesenchymal stroma: CT and angiographic appearance. J Comput Assist Tomogr (1988) 0.86
Sex steroid receptor analysis in human melanoma. Cancer (1980) 0.86
Characterization of a chimpanzee anti-human melanoma antiserum. Cancer Res (1975) 0.86
Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV. Cancer (2001) 0.85
Immunoglobulin localization in benign and malignant lesions of the human mammary gland. Cancer (1981) 0.85
Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. Cell Immunol (1997) 0.85
In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody. Ann Surg (1981) 0.84
Embryonic development of human transplantation antigens. Transplantation (1970) 0.84
Diagnosis of metastatic malignant melanoma by fine needle aspiration biopsy: a clinical and pathologic correlation of 298 cases. J Natl Cancer Inst (1986) 0.84
Clinicopathologic factors relating to surgical margins for cutaneous melanoma. Ann Surg (1993) 0.83
Human melanoma and leukemia associated antigens difined by nonhuman primate antisera. Fed Proc (1975) 0.83
Advances in the care of the patient with malignant melanoma. Ann Surg (1997) 0.83
Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2. Cell Immunol (1996) 0.83
Possibilities of immunotherapy and gene therapy for malignant melanoma. Semin Surg Oncol (1993) 0.83
Primary chondroid melanoma. J Cutan Pathol (2001) 0.83